Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Social media users are accusing the US ambassador to Israel, Mike Huckabee, of admitting that the US and Israel are using starvation as a "weapon" in Gaza. Last Friday, the head of World Health ...

Yancopoulos, M.D., Ph.D., expressed optimism about the potential of these treatments, including Libtayo ... issues with patient co-pay assistance programs. Cantor Fitzgerald’s analyst, Carter Gould, ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma ...

Q1 earnings and revenue miss expectations, mainly due to falling EYLEA sales. Stock rises on optimism around new drug approvals, pipeline progress, and upcoming FDA decisions. Don’t miss this ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS ...

Libtayo Global ... potential sales growth. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faces challenges from increased use of low-cost off-label Avastin due to patient affordability issues.

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve ... another chronic disease with a large patient population. The company also has an extremely ...